- Home
- YMAT vs BMEA Comparison
YMAT vs BMEA Comparison
Compare YMAT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAT
- BMEA
- Stock Information
- Founded
- YMAT 1970
- BMEA 2017
- Country
- YMAT Taiwan
- BMEA United States
- Employees
- YMAT N/A
- BMEA N/A
- Industry
- YMAT Recreational Games/Products/Toys
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- YMAT Consumer Discretionary
- BMEA Health Care
- Exchange
- YMAT Nasdaq
- BMEA Nasdaq
- Market Cap
- YMAT 76.4M
- BMEA 65.8M
- IPO Year
- YMAT 2025
- BMEA 2021
- Fundamental
- Price
- YMAT N/A
- BMEA $1.57
- Analyst Decision
- YMAT
- BMEA Strong Buy
- Analyst Count
- YMAT 0
- BMEA 10
- Target Price
- YMAT N/A
- BMEA $21.00
- AVG Volume (30 Days)
- YMAT 2.0M
- BMEA 957.5K
- Earning Date
- YMAT 01-01-0001
- BMEA 08-12-2025
- Dividend Yield
- YMAT N/A
- BMEA N/A
- EPS Growth
- YMAT N/A
- BMEA N/A
- EPS
- YMAT 0.07
- BMEA N/A
- Revenue
- YMAT $17,563,985.00
- BMEA N/A
- Revenue This Year
- YMAT N/A
- BMEA N/A
- Revenue Next Year
- YMAT N/A
- BMEA N/A
- P/E Ratio
- YMAT $64.10
- BMEA N/A
- Revenue Growth
- YMAT N/A
- BMEA N/A
- 52 Week Low
- YMAT $3.80
- BMEA $1.29
- 52 Week High
- YMAT $4.88
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- YMAT N/A
- BMEA 37.40
- Support Level
- YMAT N/A
- BMEA $1.72
- Resistance Level
- YMAT N/A
- BMEA $1.75
- Average True Range (ATR)
- YMAT 0.00
- BMEA 0.11
- MACD
- YMAT 0.00
- BMEA -0.02
- Stochastic Oscillator
- YMAT 0.00
- BMEA 9.20
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.